Pfizer‘s Chantix still getting the slow-burn investigation by the regulators – Federal regulators are still investigating the safety of Pfizer’s anti-smoking drug Chantix, a probe that began last year after thousands of patients reported blackouts and other problems…more Also, Pfizer at the forefront of the newest “Who wants to buy Elan??” rumors.
Merck‘s experimental Phase III heart failure drug is a…failure – Merck & Co., Inc. today said that preliminary results for the pivotal Phase III study of rolofylline (MK-7418), the Company’s investigational medicine for the treatment of acute heart failure, show that rolofylline did not meet the primary or secondary efficacy endpoints…more
The sniping begins even before GSK takes the wraps off its Avandia safety study. Not that the lawyer quoted has any ve$ted interest…it’ll be interesting to see what the data are, AND what real medical professionals have to say about the methodology and conclusions.
J&J can hardly wait to go after the premature ejaculation market – Johnson & Johnson will pursue U.S. approval for the world’s first pill to treat premature ejaculation after tests on 6,000 men showed it more than tripled the time before they reached climax. J&J will discuss approval with the Food and Drug Administration later this year, Joanne Waldstreicher, chief medical officer at the New Brunswick, New Jersey-based company, told investors and analysts today. The FDA rejected the drug in 2005. Since then, J&J has conducted three additional human trials, doubling the number of patients tested for safety and effectiveness…more
Subscribe to the Impactiviti blog via e-mail
Subscribe to the Impactiviti blog via RSS
Connect with Steve Woodruff